Twist Bioscience to Present at Fujifilm’s 12th Annual Global IT Executive Summit
June 16 2022 - 8:00AM
Business Wire
Twist Bioscience Corporation (NASDAQ: TWST), a company enabling
customers to succeed through its offering of high-quality synthetic
DNA using its silicon platform, today announced that Steffen
Hellmold, senior vice president, business development for data
storage, will present at the Fujifilm 12th Annual Global IT
Executive Summit taking place June 22-25, 2022 at the
InterContinental Hotel in San Diego, CA. Mr. Hellmold will present
on Thursday, June 23 from 3:15-3:45 PM PT in the Bayview
Ballroom.
The Summit is an exclusive, invitation only event, bringing
together industry experts, analysts, vendors and end users to
discuss trends and best practices for data management and storage,
as well as how technologies fit together to meet the challenge of
exponential data growth in the zettabyte age. In his presentation,
“Scaling up from Data Lakes to Data Oceans,” Mr. Hellmold will
discuss how DNA data storage could enable the industry to harness
the exponential data growth with affordable high-density archive
storage solutions that meet sustainability requirements.
About Twist Bioscience Corporation
Twist Bioscience is a leading and rapidly growing synthetic
biology and genomics company that has developed a disruptive DNA
synthesis platform to industrialize the engineering of biology. The
core of the platform is a proprietary technology that pioneers a
new method of manufacturing synthetic DNA by “writing” DNA on a
silicon chip. Twist is leveraging its unique technology to
manufacture a broad range of synthetic DNA-based products,
including synthetic genes, tools for next-generation sequencing
(NGS) preparation, and antibody libraries for drug discovery and
development. Twist is also pursuing longer-term opportunities in
digital data storage in DNA and biologics drug discovery. Twist
makes products for use across many industries including healthcare,
industrial chemicals, agriculture and academic research.
Follow us on Twitter | Facebook | LinkedIn | YouTube
Twist Legal Notice Regarding Forward-Looking
Statements
This press release contains forward-looking statements. All
statements other than statements of historical facts contained
herein are forward-looking statements reflecting the current
beliefs and expectations of management made pursuant to the safe
harbor provisions of the Private Securities Litigation Reform Act
of 1995. Forward-looking statements involve known and unknown
risks, uncertainties, and other important factors that may cause
Twist Bioscience’s actual results, performance, or achievements to
be materially different from any future results, performance, or
achievements expressed or implied by the forward-looking
statements. For a description of the risks and uncertainties that
could cause actual results to differ from those expressed in these
forward-looking statements, as well as risks relating to Twist
Bioscience’s business in general, see Twist Bioscience’s risk
factors set forth in Twist Bioscience’s Quarterly Report on Form
10-Q filed with the Securities and Exchange Commission on May 6,
2022 and subsequent filings with the SEC. Any forward-looking
statements contained in this press release speak only as of the
date hereof, and Twist Bioscience specifically disclaims any
obligation to update any forward-looking statement, whether as a
result of new information, future events or otherwise.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220616005357/en/
For Twist Bioscience: Angela Bitting SVP, Corporate
Affairs Twist Bioscience abitting@twistbioscience.com
Twist Bioscience (NASDAQ:TWST)
Historical Stock Chart
From Jun 2024 to Jul 2024
Twist Bioscience (NASDAQ:TWST)
Historical Stock Chart
From Jul 2023 to Jul 2024